Previous 10 | Next 10 |
Arvinas (NASDAQ: ARVN ) initiated with Buy rating and $35 (23% upside) price target at Roth Capital. More news on: Arvinas, Inc., Bicycle Therapeutics plc, Harpoon Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
NEW HAVEN, Conn., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the pricing of an underwritten public offering of 4,545,455 shares of its common stock at a price of...
NEW HAVEN, Conn., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it is commencing an underwritten public offering of $90.0 million of shares of its common stock...
Arvinas (NASDAQ: ARVN ): Q3 GAAP EPS of -$0.54 misses by $0.07 . More news on: Arvinas, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
NEW HAVEN, Conn., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financial results for the third quarter of 2019 and provided a corporate upda...
Shares of Arvinas ( ARVN ) have risen by 29% since my introductory article in April explored their early-stage research and value proposition within the very intriguing targeted protein degradation space, an approach which could have several advantages over current therapies. I'm choosing ...
Last week was an exciting one for anyone with shares of Arvinas (NASDAQ: ARVN) or Biogen (NASDAQ: BIIB) in their portfolio. Both soared more than 30% during the week ended Oct. 25, and investors who didn't have these rockets in their portfolio might feel they're missing ou...
Thinly traded Arvinas ( ARVN +13.2% ) is up on double normal volume, albeit on turnover of only 386K shares, on the heels of preliminary data from Phase 1 clinical trials evaluating the safety, tolerability and pharmacokinetics of candidates ARV-110 (metastatic castration-resistant prost...
-Data from initial cohorts suggest that Arvinas’ PROTAC® platform has the potential to create safe and well-tolerated orally bioavailable drugs for the treatment of certain cancers -Conference call to be held at 8:30 AM ET today NEW HAVEN, Conn., Oct. 23, 2019 (GLOBE N...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks T...
News, Short Squeeze, Breakout and More Instantly...
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential...
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann...